Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
What are COX inhibitors and how do you quickly get the latest development progress?
Valuable Targets
4 min read
What are COX inhibitors and how do you quickly get the latest development progress?
24 November 2023
The analysis of the target COX reveals a competitive landscape with several companies making progress in the development of COX inhibitors.
Read →
Medicenna unveils positive survival results from the Phase 2b trial of Bizaxofusp for recurrent Glioblastoma at the 28th annual NeuroOncology Society meeting
Latest Hotspot
3 min read
Medicenna unveils positive survival results from the Phase 2b trial of Bizaxofusp for recurrent Glioblastoma at the 28th annual NeuroOncology Society meeting
24 November 2023
Medicenna reports promising survival gains from the Phase 2b trial of Bizaxofusp for relapsed Glioblastoma, revealed at the 28th yearly NeuroOncology Society gathering.
Read →
EXS-21546: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
Clinical Progress
5 min read
EXS-21546: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
24 November 2023
On 14 Apr 2023, data from first-in-human study of EXS21546, an A2A receptor antagonist, was reported at the AACR Congress.
Read →
EBGLYSS® (lebrikizumab) received European Commission approval for treating moderate-to-severe atopic dermatitis
Latest Hotspot
3 min read
EBGLYSS® (lebrikizumab) received European Commission approval for treating moderate-to-severe atopic dermatitis
24 November 2023
EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.
Read →
What are CDKs inhibitors and how do you quickly get the latest development progress?
Valuable Targets
4 min read
What are CDKs inhibitors and how do you quickly get the latest development progress?
24 November 2023
The development of inhibitors around the entire CDK family has become an important branch of drug development in the field of oncology in recent years.
Read →
US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
Latest Hotspot
3 min read
US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
24 November 2023
US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.
Read →
An analysis of LY-3537982's R&D progress and its clinical results presented at the 2023 AACR Annual Meeting
Clinical Progress
4 min read
An analysis of LY-3537982's R&D progress and its clinical results presented at the 2023 AACR Annual Meeting
24 November 2023
The initial results from LOXO-RAS-20001, a phase 1 study of LY3537982 in patients (pts) with KRAS G12C-mutant advanced solid tumors were reported at the AACR Congress.
Read →
Polaris Group begins phased BLA submission for ADI-PEG 20 to the U.S. FDA for Malignant Pleural Mesothelioma management
Latest Hotspot
3 min read
Polaris Group begins phased BLA submission for ADI-PEG 20 to the U.S. FDA for Malignant Pleural Mesothelioma management
24 November 2023
Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.
Read →
What are ERK inhibitors and how do you quickly get the latest development progress?
Valuable Targets
4 min read
What are ERK inhibitors and how do you quickly get the latest development progress?
24 November 2023
Inhibiting the downstream ERK can block cell signal transduction, and ERK inhibitors can overcome tumor cells' resistance to upstream target inhibitors. This gives them broader application prospects in clinical settings.
Read →
FDA approves XTANDI® for advanced prostate cancer treatment
Latest Hotspot
3 min read
FDA approves XTANDI® for advanced prostate cancer treatment
24 November 2023
Astellas and Pfizer's XTANDI® gets FDA approval for update, following fast-tracked review and EMBARK study results.
Read →
Decoding Axatilimab: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
Clinical Progress
5 min read
Decoding Axatilimab: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
24 November 2023
On 11 Dec 2023, the updated clinical results of Axatilimab at 3 different doses in patients with Chronic Graft-Versus-Host Disease (AGAVE-201) will be reported in 2023 ASH.
Read →
Q32 Bio retrieves global rights for Bempikibart (ADX-914) back from Amgen
Latest Hotspot
3 min read
Q32 Bio retrieves global rights for Bempikibart (ADX-914) back from Amgen
24 November 2023
Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.
Read →